Cardiovascular multimorbidity: the effect of ethnicity on prevalence and risk factor management

Rohini Mathur1, Sally A Hull, Ellena Badrick

  • 1Centre for Health Sciences, Queen Mary University of London, London, UK. r.mathu@qmul.ac.uk

Insights

Cardiovascular multimorbidity is more prevalent in non-white ethnic groups. While risk factor management improves with more conditions, ethnic disparities persist, contributing to health inequalities.

Area of Science:

  • Cardiology
  • Public Health
  • Health Services Research

Background:

  • Multimorbidity, particularly cardiovascular disease, is prevalent in primary care.
  • Recognized ethnic variations exist in cardiovascular disease prevalence and risk factor management.

Purpose of the Study:

  • To assess the population burden of cardiovascular multimorbidity.
  • To examine modifiable cardiovascular risk factor management across different ethnicities.

Main Methods:

  • Cross-sectional study of 843,720 individuals across 148 general practices in East London.
  • Utilized MIQUEST data from cardiovascular registers; employed logistic regression for multimorbidity risk and risk factor control analysis by ethnicity.

Main Results:

  • Crude prevalence of cardiovascular multimorbidity was 34%.
  • Non-white ethnic groups showed higher multimorbidity risk (South Asians OR 2.04, Black ethnicity OR 1.23).
  • Risk factor control (blood pressure, cholesterol, HbA1c) improved with multimorbidity, but ethnic differences persisted.

Conclusions:

  • Cardiovascular multimorbidity burden and risk factor management vary significantly by ethnicity.
  • Despite improvements with higher morbidity, persistent ethnic disparities in risk factor control contribute to health inequalities.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...